<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00651144</url>
  </required_header>
  <id_info>
    <org_study_id>P03317</org_study_id>
    <nct_id>NCT00651144</nct_id>
  </id_info>
  <brief_title>Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)</brief_title>
  <official_title>SCH 058235: Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Rosuvastatin in Healthy Hypercholesterolemic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain data of the coadministration of ezetimibe and&#xD;
      rosuvastatin to support the concomitant use of these two drugs in patients requiring&#xD;
      additional cholesterol-lowering management. Treatment is administered for 14 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in total cholesterol, LDL-C, HDL-C, and triglycerides.</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: adverse events, laboratory test results, physical examination, vital signs.</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate potential for PK interaction between ezetimibe and rosuvastatin as indicated by Cmax and AUC.</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Ezetimibe + Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe + Rosuvastatin</intervention_name>
    <description>oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days</description>
    <arm_group_label>Ezetimibe + Rosuvastatin</arm_group_label>
    <other_name>Zetia</other_name>
    <other_name>SCH 58235</other_name>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablets; two ezetimibe placebo once daily for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <other_name>Zetia</other_name>
    <other_name>SCH 58235</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females between the ages of 18 and 55 years inclusive, having a Body Mass&#xD;
             Index (BMI) between 19-31 inclusive. BMI=weight (kg)/height (m^2).&#xD;
&#xD;
          -  Subjects must have untreated hypercholesterolemia with a directly measured fasting&#xD;
             LDL-C &gt;=130 mg/dL (3.37 mmol/L) at Screening and on Day -1. Subjects must be free of&#xD;
             any clinically significant disease that requires a physician's care and/or would&#xD;
             interfere with the study evaluations.&#xD;
&#xD;
          -  Subjects must have a normal or clinically acceptable physical exam and ECG (12-lead&#xD;
             recorded at 25 mm/s and reporting heart rate and PR, QRS, QT, and QTc intervals).&#xD;
&#xD;
          -  Subjects' clinical laboratory tests (CBC, blood chemistries, and urinalysis) must be&#xD;
             within normal limits or clinically acceptable to the investigator/ sponsor.&#xD;
&#xD;
          -  Screen for drugs with high potential for abuse must be negative.&#xD;
&#xD;
          -  Subjects must be willing to give written informed consent and able to adhere to dose&#xD;
             and visit schedules.&#xD;
&#xD;
          -  Subjects must be willing to comply with the NCEP Step 1 diet for at least one week as&#xD;
             outpatients, and during the inpatient treatment period.&#xD;
&#xD;
          -  Female subjects must be of nonchildbearing potential (ie, surgically sterilized or&#xD;
             postmenopausal for at least one year), or, if they are of childbearing potential they&#xD;
             must be using a medically accepted method of birth control prior to Screening and&#xD;
             agree to continue its use during the study or be surgically sterilized (eg,&#xD;
             hysterectomy or tubal ligation). Females of childbearing potential should be counseled&#xD;
             in the appropriate use of birth control while in this study. Females who are not&#xD;
             currently sexually active must agree and consent to use one of the above-mentioned&#xD;
             methods should they become sexually active while participating in the study.&#xD;
&#xD;
          -  Female subjects must have a negative serum pregnancy test (beta-hCG) at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects who are pregnant, intend to become pregnant, or are nursing.&#xD;
&#xD;
          -  Subjects who previously received or were treated with ezetimibe (SCH 58235) or&#xD;
             rosuvastatin.&#xD;
&#xD;
          -  Subjects who previously received or were treated with lipid lowering drugs (including&#xD;
             OTC fish oil and phytosterols) within 6 weeks of Visit 1.&#xD;
&#xD;
          -  Any subject who does not comply with the requirement that he/she should not have used&#xD;
             any prescription or over-the-counter drugs (except for aspirin or acetaminophen&#xD;
             [paracetamol]) within two weeks prior to study drug administration nor alcohol within&#xD;
             48 hours prior to study drug administration.&#xD;
&#xD;
          -  Subjects who have used any investigational drugs or donated blood within 30 days of&#xD;
             study entry.&#xD;
&#xD;
          -  Subjects with pre-existing gallbladder disease or a history of liver function test&#xD;
             abnormalities.&#xD;
&#xD;
          -  Subjects who smoke more than ten cigarettes or equivalent tobacco use per day.&#xD;
&#xD;
          -  Subjects who have a clinically significant allergy or intolerance to foods or drugs,&#xD;
             especially to any component of ezetimibe (ZETIA™/EZETROL™) or rosuvastatin (CRESTOR™).&#xD;
&#xD;
          -  Subjects who are positive for HIV antibodies, hepatitis B surface antigen or hepatitis&#xD;
             C antibody.&#xD;
&#xD;
          -  Subjects with a history of mental instability or who have been or are being treated&#xD;
             for mood disorders.&#xD;
&#xD;
          -  Subjects who are in a situation or have any condition that, in the opinion of the&#xD;
             investigator, may interfere with optimal participation in the study.&#xD;
&#xD;
          -  Subjects who are participating in any other clinical study.&#xD;
&#xD;
          -  Subjects who are part of the staff personnel directly involved with this study.&#xD;
&#xD;
          -  Subjects who are a family member of the investigational study staff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, Maxwell SE, Tiessen R, Cutler DL. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004 Aug;20(8):1185-95.</citation>
    <PMID>15324521</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>April 15, 2015</last_update_submitted>
  <last_update_submitted_qc>April 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

